CVI Holdings’s Gossamer Bio GOSS Stock Holding History

CVI Holdings’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,201	Closed	-$813K	–	196
2023 Q3	$813K	Buy	+12,201	New	+$1.12M	1.61%	21

Other funds holding GOSS

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

CVI Holdings's GOSS Position: Q4 2023 in Review

CVI Holdings sold out of Gossamer Bio (GOSS) in Q4 2023, closing a stake of 12,201 shares — an estimated $813K sold.

CVI Holdings first reported a position in GOSS in Q3 2023 and held it in 1 quarter. The position peaked at $813K in Q3 2023. 96 funds tracked by Wall St. Rank hold GOSS as of Q4 2023.

CVI Holdings reported no remaining Gossamer Bio position as of Q4 2023 after selling out during the quarter.
CVI Holdings sold 12,201 Gossamer Bio shares in Q4 2023, an estimated $813K.
CVI Holdings first reported a position in Gossamer Bio in Q3 2023 and held it in 1 quarter.
CVI Holdings's Gossamer Bio position peaked at $813K in Q3 2023.
96 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2023.

Based on CVI Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.